Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, Maryland.
J Infect Dis. 2019 Jan 29;219(4):633-636. doi: 10.1093/infdis/jiy373.
Matrix metalloproteinases (MMPs) degrade extracellular matrix and are implicated in tuberculosis pathogenesis and cavitation. In particular, MMP-7 is induced by hypoxia and highly expressed around pulmonary cavities of Mycobacterium tuberculosis-infected C3HeB/FeJ mice. In this study, we evaluated whether administration of cipemastat, an orally available potent inhibitor of MMP-7, could reduce pulmonary cavitation in M. tuberculosis-infected C3HeB/FeJ mice. We demonstrate that, compared with untreated controls, cipemastat treatment paradoxically increases the frequency of cavitation (32% vs 7%; P = .029), immunopathology, and mortality. Further studies are needed to understand the role of MMP inhibitors as adjunctive treatments for pulmonary tuberculosis.
基质金属蛋白酶(MMPs)降解细胞外基质,与结核病发病机制和空洞形成有关。特别是,MMP-7 由缺氧诱导,在感染结核分枝杆菌的 C3HeB/FeJ 小鼠的肺部空洞周围高度表达。在这项研究中,我们评估了口服有效 MMP-7 抑制剂西派司他是否可以减少感染结核分枝杆菌的 C3HeB/FeJ 小鼠的肺部空洞形成。我们发现,与未治疗的对照组相比,西派司他治疗反而增加了空洞形成的频率(32%对 7%;P=0.029)、免疫病理学和死亡率。需要进一步研究来了解 MMP 抑制剂作为辅助治疗肺结核的作用。